Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
Identifieur interne : 003470 ( Main/Curation ); précédent : 003469; suivant : 003471Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
Auteurs : Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-12.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Levodopa, Levodopa (therapeutic use), L‐dopa, Male, Middle Aged, Nervous system diseases, Outcome Assessment (Health Care), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Piribedil, Piribedil (therapeutic use), Severity of Illness Index, Single-Blind Method, Time Factors, monotherapy, piribedil.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa, Piribedil.
- drug therapy : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Severity of Illness Index, Single-Blind Method, Time Factors.
Abstract
Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21122
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001064
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001064
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001F30
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A59
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002A59
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002D61
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001880
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001880
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001880
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004784
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001877
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001444
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001B31
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004C26
Links to Exploration step
ISTEX:4978C7624F02F4B0130A6FACC88D4C85DA47167DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
</author>
<author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name>
</author>
<author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4978C7624F02F4B0130A6FACC88D4C85DA47167D</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21122</idno>
<idno type="url">https://api.istex.fr/document/4978C7624F02F4B0130A6FACC88D4C85DA47167D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001064</idno>
<idno type="wicri:Area/Istex/Curation">001064</idno>
<idno type="wicri:Area/Istex/Checkpoint">001F30</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:early:piribedil:monotherapy</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17013922</idno>
<idno type="wicri:Area/PubMed/Corpus">002A59</idno>
<idno type="wicri:Area/PubMed/Curation">002A59</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D61</idno>
<idno type="wicri:Area/Ncbi/Merge">001880</idno>
<idno type="wicri:Area/Ncbi/Curation">001880</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001880</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:early:piribedil:monotherapy</idno>
<idno type="wicri:Area/Main/Merge">004784</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0090862</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001877</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001444</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001B31</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:early:piribedil:monotherapy</idno>
<idno type="wicri:Area/Main/Merge">004C26</idno>
<idno type="wicri:Area/Main/Curation">003470</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Instituto de Ciënsas da Saùde, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Statistics, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherches Internationales Servier, Courbevoie</wicri:regionArea>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Courbevoie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-12">2006-12</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="2110">2110</biblScope>
<biblScope unit="page" to="2115">2115</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">4978C7624F02F4B0130A6FACC88D4C85DA47167D</idno>
<idno type="DOI">10.1002/mds.21122</idno>
<idno type="ArticleID">MDS21122</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>L‐dopa</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Outcome Assessment (Health Care)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Piribedil</term>
<term>Piribedil (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Time Factors</term>
<term>monotherapy</term>
<term>piribedil</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Outcome Assessment (Health Care)</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Piribédil</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2006:Rascol O:early:piribedil:monotherapy"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early piribedil monotherapy of Parkinson's disease : A planned seven-month report of the REGAIN study</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM U610/Gmupe Hospitalier Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Instituto de Ciënsas da Saùde</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Instituto de Ciënsas da Saùde</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Statistics, University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
<orgName type="university">Université de Glasgow</orgName>
</affiliation>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0090862</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 07-0090862 INIST</idno>
<idno type="RBID">Pascal:07-0090862</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001877</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001444</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001B31</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:early:piribedil:monotherapy</idno>
<idno type="wicri:Area/Main/Merge">004C26</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early piribedil monotherapy of Parkinson's disease : A planned seven-month report of the REGAIN study</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>INSERM U610/Gmupe Hospitalier Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Instituto de Ciënsas da Saùde</s1>
<s2>Lisbon</s2>
<s3>PRT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
<wicri:noRegion>Instituto de Ciënsas da Saùde</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name>
<affiliation wicri:level="4"><inist:fA14 i1="04"><s1>Department of Statistics, University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
<orgName type="university">Université de Glasgow</orgName>
</affiliation>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut de Recherches Internationales Servier</s1>
<s2>Courbevoie</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
<wicri:noRegion>Institut de Recherches Internationales Servier</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Piribédil</term>
<term>Lévodopa</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Piribedil is a D<sub>2</sub>
dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L-dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7-month period. Four hundred and five early PD patients were randomized (double-blind) to piribedil (150-300 mg/day) or placebo. L-dopa open-label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (-4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38-9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82-7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by -1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8-3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26-6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
</author>
<author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name>
</author>
<author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4978C7624F02F4B0130A6FACC88D4C85DA47167D</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.21122</idno>
<idno type="url">https://api.istex.fr/document/4978C7624F02F4B0130A6FACC88D4C85DA47167D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001064</idno>
<idno type="wicri:Area/Istex/Curation">001064</idno>
<idno type="wicri:Area/Istex/Checkpoint">001F30</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:early:piribedil:monotherapy</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17013922</idno>
<idno type="wicri:Area/PubMed/Corpus">002A59</idno>
<idno type="wicri:Area/PubMed/Curation">002A59</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D61</idno>
<idno type="wicri:Area/Ncbi/Merge">001880</idno>
<idno type="wicri:Area/Ncbi/Curation">001880</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001880</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:early:piribedil:monotherapy</idno>
<idno type="wicri:Area/Main/Merge">004784</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Clinical Investigation Center and Departments of Clinical Pharmacology and Neurosciences, Faculté de Médecine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U610/Groupe Hospitalier Pitié‐Salpêtrière, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Caldas, Alexandre Castro" sort="Caldas, Alexandre Castro" uniqKey="Caldas A" first="Alexandre Castro" last="Caldas">Alexandre Castro Caldas</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Instituto de Ciënsas da Saùde, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Senn, Stephen" sort="Senn, Stephen" uniqKey="Senn S" first="Stephen" last="Senn">Stephen Senn</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Statistics, University of Glasgow, Glasgow</wicri:regionArea>
<orgName type="university">Université de Glasgow</orgName>
<placeName><settlement type="city">Glasgow</settlement>
<region type="country">Écosse</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherches Internationales Servier, Courbevoie</wicri:regionArea>
<wicri:noRegion>Courbevoie</wicri:noRegion>
<wicri:noRegion>Courbevoie</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Royal Free and University College Medical School, University College London/Reta Lila, Weston Institute of Neurological Studies, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-12">2006-12</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="2110">2110</biblScope>
<biblScope unit="page" to="2115">2115</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">4978C7624F02F4B0130A6FACC88D4C85DA47167D</idno>
<idno type="DOI">10.1002/mds.21122</idno>
<idno type="ArticleID">MDS21122</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>L‐dopa</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Outcome Assessment (Health Care)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Piribedil (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Time Factors</term>
<term>monotherapy</term>
<term>piribedil</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Outcome Assessment (Health Care)</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Piribedil is a D2 dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred and five early PD patients were randomized (double‐blind) to piribedil (150–300 mg/day) or placebo. L‐dopa open‐label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement > 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (−4.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38–9.14; P < 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82–7.80; P < 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by −1.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8–3.62; P < 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26–6.11; P < 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003470 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003470 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:4978C7624F02F4B0130A6FACC88D4C85DA47167D |texte= Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |